The U.S. Department of Health and Human Services has notified Moderna (MRNA) that it will terminate funding for the late-stage development of pre-pandemic influenza vaccines, along with the right to purchase them. Meanwhile, Moderna said it will explore alternatives for late-stage development and manufacturing of the H5 program consistent with the company's strategic commitment to pandemic preparedness.
After a rigorous review, HHS reportedly concluded that further investment in Moderna's H5N1 mRNA vaccine is neither scientifically nor ethically justifiable. HHS Communications Director Andrew Nixon reportedly stated that the decision was based on careful assessment of available data and broader public health consideration.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.